Navigation Links
Gene Tests Match Up Lung Tumors, Best Treatment
Date:10/3/2007

DNA indicates whether chemo will work, experts say

WEDNESDAY, Oct. 3 (HealthDay News) -- Identifying a lung tumor's genetic profile may help doctors determine the best chemotherapy for patients, U.S. research suggests.

"We were able to predict which tumors would be most likely to respond to standard first-line therapy and which would respond better to what has traditionally been a second-line therapy, based on gene expression profiling," lead author and oncologist Dr. David Hsu, of Duke University in Durham, N.C., said in a prepared statement.

"This represents a big step in the move toward individualized medicine," he said. "This could also make a huge difference in the treatment of patients with late-stage lung cancer, as most of these patients gain the most benefit from their initial treatment strategy."

The findings are published in the Oct. 1 issue of the Journal of Clinical Oncology.

The researchers determined that there are distinct differences in lung tumors' susceptibility to chemotherapy drugs.

In the first part of the study, Hsu's team found that certain genes expressed in non-small cell lung cancer (NSCLC) tumors known to be sensitive to cisplatin (the most commonly-used agent in the treatment of lung cancer) were not expressed in tumors known to be resistant to cisplatin. They also found that genes expressed in the tumors resistant to cisplatin were expressed in tumors sensitive to it.

In the next phase of the research, the team examined a number of second-line therapies for lung cancer, including pemetrexed, which uses a different mechanism of action to fight NSCLC tumors.

"We found the strongest inverse correlation between tumors that were sensitive to cisplatin and those that were sensitive to pemetrexed," senior author and oncologist Dr. Anil Potti said in a prepared statement. "This suggests that some patients who are not likely to respond to cisplatin should perhaps be treated with pemetrexed first."

The findings have formed the basis of a clinical trial -- the first of its kind in lung cancer -- currently being conducted at Duke University.

"These are not experimental drugs; we know they work. It's just a matter of giving each patient the right one on the first try," Potti said.

More information

The American Medical Association has more about lung cancer.



-- Robert Preidt



SOURCE: Duke University, news release, Sept. 28, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. IMA wants members not to do sex determination tests during pregnancy
2. Doctors advice early anemia tests
3. Early diagnosis for autism from blood tests may be possible
4. FDA approves Phase 0 trial which tests experimental drugs on humans
5. Genetic tests for cancer
6. Space research leads to needle-free blood tests
7. The Effectiveness Of Screening Tests Questioned
8. Blood Tests Can Help Detect Osteoporosis Early In Life
9. Easier Tests To Detect Tuberculosis
10. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
11. Skin tests confirms cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of ... from 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier ... the number of citations received by the journal over a three year period and ...
(Date:2/11/2016)... ... 2016 , ... The president released a FY 2017 budget request on Tuesday ... of the cost burden to military beneficiaries. , MOAA’s president, retired Air Force ... as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We ...
(Date:2/11/2016)... ... 11, 2016 , ... Hall Integrative Health and Chiropractic, PC ... simultaneous grand openings in March. All seven practices are set to start accepting ... reversing diabetes possible? According to this 2011 CNN article it is possible: ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... women’s health, is pleased to announce the promotions of Allison Kelly to executive ... Steve Catone to executive vice president of North American capital sales, and Wendy ...
(Date:2/11/2016)... ... 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... Study for Plans and Purchasers.” Executives from Intel Corp. and Providence Health & ... health benefits program Connected Care, will discuss the challenges they faced (and how ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Fla. , Feb. 11, 2016 ... ) company providing high-quality specialty pharmacy care for ... announced today it has achieved full Specialty Pharmacy ... accrediting organization dedicated to promoting health care quality ... --> --> The URAC accreditation ...
(Date:2/11/2016)... , Feb. 11, 2016  M3 Biotechnology Inc., spurred by a major "team investment" by ... brother, Michael, has completed an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... ...
(Date:2/11/2016)... 11, 2016 SI-BONE, Inc., a medical ... iFuse Implant System, a minimally invasive surgical (MIS) ... the sacroiliac (SI) joint, announced the publication of ... MIS SI joint fusion for patients suffering from ... or SI joint disruption.  In the first article, ...
Breaking Medicine Technology: